Join our daily newsletter At The Bell to receive exclusive market insights
- Dimerix (DXB) releases its pipeline program DMX-700 study results which indicates a significant 80 per cent reduction in lung injury in mice
- The study showed “very encouraging and statistically significant” pre-clinical data that strongly supports further development of DMX-700
- Further intellectual property is identified and an additional patent application is underway
- The clinical trial will now be designed, along with any further required nonclinical safety studies, with the initial clinical study expected to commence first half 2023
- Shares in Dimerix are up 20 per cent to trade at 15 cents as of 12:16 pm AEST
Dimerix (DXB) has released its pipeline program DMX-700 study results which indicated a significant 80 per cent reduction in lung injury in mice.
DMX-700 was identified as a novel oral candidate for the treatment of chronic obstructive pulmonary disease (COPD) using Dimerix proprietary Receptor-HIT platform.
The study showed “very encouraging and statistically significant” pre-clinical data that strongly supports further development of DMX-700, which was tested in mice using an oral dose delivery in the porcine pancreatic elastase (PPE) model of COPD.
The PPE model is the mostly commonly used COPD model as it mimics the inflammatory response in the lungs of mice and leads to breakdown of lung tissue and shortness of breath.
CEO and Managing Director Nina Webster said the information should provide significant encouragement to clinical investigators and patients in the company’s clinical trials of DMX-700.
“We have established that blocking the known targets of COPD with DMX-700 at the same time results in a statistically significant decrease in lung injury that leads to fibrosis, or scarring,” Dr Webster said.
“Our now expanding clinical pipeline will strengthen our ongoing discussions with potential commercial and strategic partners.”
Further intellectual property has been identified and an additional patent application is underway.
The DMX-700 compounds individually have a known safety profile in human studies, meaning DMX-700 may potentially move directly into clinical studies, subject to regulatory approvals.
The clinical trial will now be designed, along with any further required nonclinical safety studies, with the initial clinical study expected to commence first half 2023.
Shares in Dimerix were up 20 per cent to trade at 15 cents as of 12:16 pm AEST.
